HFV 1017
Alternative Names: HFV 1017CLatest Information Update: 17 Jan 2001
At a glance
- Originator Daiichi Fine Chemical
- Class Antithrombotics
- Mechanism of Action Platelet aggregation inhibitors; Type 1 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis